UGenome

Bone Metastasis Risk Analysis in Breast Cancer

Company: Startup focusing on breast cancer detection
Date: May 2023

Bone metastasis risk in breast cancer treatment

  • Client had access to RNA-seq data from breast cancer patients before treatment with Nintenab*
  • UGenome pre-processed and aligned the RNA-seq data to a reference genome.
  • UGenome converted the aligned RNA-seq data to transcripts per million and calculated a MeCo score for each patient.

*Nintedanib is used to treat idiopathic pulmonary fibrosis

Get Started